Are you looking for faster enrollment, stronger site performance, and more predictable outcomes in an evolving obesity landscape? Today’s obesity trials are more complex and competitive than ever. IQVIA’s team of seasoned experts, integrated analytics, and globally coordinated trial execution can help you.
Complex risk indications, including ischemic heart disease, hypertension, dyslipidemia, heart failure, atrial fibrillation, and peripheral artery disease require seasoned expertise.
Therapeutic expertise with obesity-driven endocrine indications, including Type 2 diabetes mellitus and gestational diabetes, can help inform your trial strategies.
Cross-therapeutic expertise is key to address complex hormonal, metabolic, and functional endpoints, covering indications such as polycystic ovarian syndrome, erectile dysfunction, and urinary incontinence.
Obesity can increase the risk of many types of cancer, including breast, colon, liver and pancreatic cancer.
A successful trial strategy reflects the intersection of metabolic and neurological disease including experience with indications such as migraines, depression, and pseudotumor cerebri.
We have in-depth experience supporting obesity-related respiratory indications, including chronic obstructive pulmonary disease, asthma, and obstructive sleep apnea, enabling integrated approaches across overlapping respiratory and metabolic pathways.
Trials in obesity-driven GI and liver diseases are difficult to design and execute due to shifting endpoints, comorbid populations, and regulatory uncertainty. Our experience in MASH, GERD, and gallbladder disease helps reduce complexity, optimize study design, and accelerate development across liver and metabolic pathways.
Obesity adds complexity to rheumatology trials, from patient variability to endpoint measurement. Our experience in gout and osteoarthritis helps de-risk design, improve execution, and deliver stronger outcomes.
The global burden of obesity is rising, with 1 billion people worldwide expected to have obesity by 2030.
IQVIA is redefining the obesity clinical trial experience with innovative strategies that accelerate patient recruitment, enhance site operations, and ensure robust, reliable data collection. By embedding COA-driven strategies, we help sponsors differentiate assets in a crowded market and demonstrate meaningful patient impact.
Overweight and obese trials, including diabetes, obesity, and CV trials
Implications of new guidance for the obesity market and innovators
The IQVIA Institute offers stakeholder data, evidence and insights about important topics related to obesity, such as research methodologies, health economic implications and more.
Stay ahead of the curve by taking advantage of our industry insights on the global health challenges around obesity.
Did you know? Beyond trial design and patient engagement, IQVIA also offers expert-led, advanced laboratory services to support rapid obesity drug development, including bioanalysis and pharmacokinetics for GLP-1/GIP therapies.
Our team are dedicated to supporting your journey in the evolving clinical trials landscape. Whether you're advancing your first asset or scaling globally, we have the expertise and resources to help you navigate the complexities of today's environment.
We would love to discuss how these insights can be applied to your specific needs and explore potential collaboration opportunities.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Fast, flexible and proven, IQVIA’s industry-leading electronic clinical outcome assessment (eCOA) platform ramps up efficiencies, delivers real-time data, and sharpens insights through best-in-class technology and a better patient experience.
Leverage a global network of Phase I clinical pharmacology units to build diversity in patient populations and access a range of geographic regions for early clinical development (ECD) programs.
Predict enrollment more accurately and increase the number of patients per site using data-driven patient recruitment solutions.
Helping Sites and Investigators grow through innovation and collaboration
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.
Understanding what to measure is a key component in obesity and related trials. COAs can be used to capture meaningful patient data, address comorbidities, and to help determine a strategy to optimize your trial. Explore more about how you can leverage COAs in your trials.
IQVIA supports modern obesity clinical research by uniting deep therapeutic expertise with advanced technology. Our global site networks accelerate patient recruitment and ensure high-quality clinical data collection.
We support the full spectrum of obesity clinical research programs, including the investigation of next-generation therapies. Our Obesity Center of Excellence further integrates expertise across endocrinology, cardiometabolic disease, and regulatory strategy.
IQVIA has extensive experience in GLP-1 clinical trials. Every GLP-1 therapy approved in the past five years has utilized IQVIA services across clinical development and patient access. We have conducted more than 100 obesity drug trials worldwide. This extends to include trials actively expanding beyond diabetes and obesity.
We further support sponsors with advancing next-generation GLP-1–based obesity treatments. Our expertise spans end-to-end clinical development, from protocol design and patient recruitment to regulatory approval and market access.
.svg){kind=icon}
